- Home
- Products
- Customized ADCs
- E. coli Stx2B
- Anti-E. coli Stx2B (Urtoxazumab)-MC-MMAF ADC
Anti-E. coli Stx2B (Urtoxazumab)-MC-MMAF ADC (CAT#: ADC-W-2140)
This ADC product is comprised of an anti-E. coli Stx2B monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- E. coli Stx2B
- Alternative Names
- E. coli Stx2B
- Overview
- Shiga toxins are a family of related toxins with two major groups, Stx1 and Stx2, expressed by genes considered to be part of the genome of lambdoid prophages. The toxin has two subunits—designated A(mol. wt. 32000 D) and B(mol. wt. 7700 D)—and is one of the AB5 toxins. The B subunit is a pentamer that binds to specific glycolipids on the host cell, specifically globotriaosylceramide (Gb3). Following this, the A subunit is internalised and cleaved into two parts. The A1 component then binds to the ribosome, disrupting protein synthesis.
- Overview
- Humanized Anti-E. coli Stx2B IgG1-kappa antibody, Urtoxazumab
- Generic name
- Urtoxazumab
- Host animal
- Mouse
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-EphA2 -VC-MMAE ADC-1 (CAT#: ADC-W-398)
- Anti-IL23A (Guselkumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1351)
- Anti-APP (Bapineuzumab)-SMCC-DM1 ADC (CAT#: ADC-W-704)
- Anti-CD28 (lulizumab pegol)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2333)
- Anti-CD33-Mc-VC-SGD-1882 ADC-7 (CAT#: ADC-W-492)
- Anti-FGFR2-sulfo-SMCC-DM1 ADC-4 (CAT#: ADC-W-054)
- Anti-TNFRSF8 (Iratumumab)-SPDB-DM4 ADC (CAT#: ADC-W-1887)
- Anti-CEACAM5 (Altumomab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-971)
- Anti-IGF2 (Dusigitumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1273)
- Anti-PVRL4 (Enfortumab vedotin)-SPDB-DM4 ADC (CAT#: ADC-W-2397)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-2140. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-2139 | Anti-E. coli Stx2B (Urtoxazumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-2138 | Anti-E. coli Stx2B (Urtoxazumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-2143 | Anti-E. coli Stx2B (Urtoxazumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2142 | Anti-E. coli Stx2B (Urtoxazumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2141 | Anti-E. coli Stx2B (Urtoxazumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| CAT# | Product Name | Linker | Payload |
| ADC-W-114 | Anti-CD33-Mc-MMAF ADC-3 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-2606 | Anti-ITGB3 (Tadocizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-515 | Anti-EGFR-Mc-MMAF ADC-5 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-115 | Anti-CD33-Mc-MMAF ADC-1 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-491 | Anti-TNFRSF17-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2567 | Anti-MUC16 (Sofituzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2612 | Anti-MS4A1 (Rituximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2544 | Anti-CD44 (Bivatuzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2561 | Anti-MSLN (Anetumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-AA-064 | Anti-HIgG(Fab)-C-MMAF ADC | Cleavable linkers | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.